menu
    • menu
    [{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Naproxen Sodium","moa":"COX","graph1":"Neurology","graph2":"Approved","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Miravo Healthcare \/ Orion Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Miravo Healthcare \/ Orion Corporation"},{"orgOrder":0,"company":"Miravo Healthcare","sponsor":"Aralez Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Miravo Healthcare","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Miravo Healthcare \/ Miravo Healthcare","highestDevelopmentStatusID":"12","companyTruncated":"Miravo Healthcare \/ Miravo Healthcare"}]

    Find Clinical Drug Pipeline Developments & Deals by Miravo Healthcare

    Menu

    Miravo Healthcare

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Miravo Healthcare

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Miravo Healthcare

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Aralez Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Miravo Healthcare™ Announces the Canadian Commercial Launch of Blexten® for Patients 4 Years of Age and Old...

                            Details : Blexten (bilastine) is a second-generation antihistamine drug, exerts its effect through its highly selective inhibition of peripheral histamine H1 receptors for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria.

                            Brand Name : Blexten

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 01, 2022

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Aralez Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Miravo Healthcare

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Miravo Healthcare

                            Canada arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Miravo Healthcare Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select ...

                            Details : Miravo Healthcare, has entered into an exclusive license and supply agreement with Orion Corporation for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estoni...

                            Brand Name : Suvexx

                            Molecule Type : Small molecule

                            Upfront Cash : $2.0 million

                            December 21, 2020

                            Lead Product(s) : Naproxen Sodium,Sumatriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Orion Corporation

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth